Comparison of Clinical Efficacy and Safety between 70–150 µm and 100–300 µm Doxorubicin Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma

Comparison of Clinical Efficacy and Safety between 70–150 µm and 100–300 µm Doxorubicin Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma

Background: This study aimed to compare the efficacy and safety of 70–150 μm doxorubicin drug-eluting bead (DEB) transarterial chemoembolization (TACE) with those of 100–300 μm DEB-TACE as first-line treatment in patients with hepatocellular carcinoma (HCC). Methods: We retrospectively investigated...

Full description

Bibliographic Details
Main Authors: Jung Woo Yi, Hyun Pyo Hong, Myung Sub Kim, Byung Seok Shin, Heon-Ju Kwon, Byung Ik Kim, Won Sohn
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Life
Subjects:
hepatocellular carcinoma
transcatheter arterial chemoembolization
doxorubicin drug-eluting beads
response
safety
Online Access:https://www.mdpi.com/2075-1729/12/2/297

Internet

https://www.mdpi.com/2075-1729/12/2/297

Similar Items